Journals / Güncel Pediatri / 2010 / Cilt: 8 Sayı: 3

Cardiac Involvement in Mucopolysaccharidoses

Mukopolisakkaridozlarda Kardiyak Tutulum

Kadir Babaoğlu(Kocaeli Üniversitesi Tıp Fakültesi Çocuk Sağlığı ve Hastalıkları Anabilim Dalı Kocaeli, Türkiye)
Gamze Özsoy(Kocaeli Üniversitesi Tıp Fakültesi Çocuk Kardiyolojisi Bilim Dalı Kocaeli, Türkiye)
Köksal Binnetoğlu(Kocaeli Üniversitesi Tıp Fakültesi Çocuk Kardiyolojisi Bilim Dalı Kocaeli, Türkiye)
Pages
48–51
Publication Date
2010-12-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Echocardiographic examination should be performed periodically even if the patient has no clinical signs of cardiac disease

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Mucopolysaccharidoses MPS are an important group of lysosamal storage diseases.
📊
Key Findings & Data:Materials and Method: We studied a total of 11 children with MPS who were admitted to our department between 2005 and 2009.
💡
Conclusion & Impact:Echocardiographic examination should be performed periodically even if the patient has no clinical signs of cardiac disease
🔬Design:Makale
📍Scope:2005 Verileri
⚙️Variables:Mukopolisakkaridozlar · çocuklar · ekokardiyografi

Abstract

Introduction: Mucopolysaccharidoses MPS are an important group of lysosamal storage diseases. Commonly reported cardiac involvements are mitral leaflet thickening and accompanying prolapsus, regurgitation and rarely stenosis. In this study,it was aimed to evaluate cardiac in involvements in patients with MPS. Materials and Method: We studied a total of 11 children with MPS who were admitted to our department between 2005 and 2009. Cardiac status was evaluatedretrospectively with telecardiography, electrocardiography and echocardiography. Results: The ages of the patients 6 girls and 5 boys ranged between 1.5-14 years andthe mean age was 7.44±5.35 median 7 years. Each of Type II and IV were identifiedin three patients; type I in two and type VI in one. In two patients, MPS type has notbeen identified yet. Thickening of the mitral valve with or without regurgitaion andprolapsus was the most common lesion seen in all patients. Additional involvement ofthe aortic valve was detected in 4 36.3% and additional involvement of tricuspidvalve in 2 patients. Septal hypertrophy was found in one patient and pulmonary hypertension in another. No arrhythmia was found in any patient.Conclusion: Cardiac involvement is frequent in MPS. Mitral valve deformation is themost frequent finding. Echocardiographic examination should be performed periodically even if the patient has no clinical signs of cardiac disease

Özet

Giriş: Mukopolisakkaridozlar MPS , lizozomal depo hastalıklarının önemli birgrubudur. Literatürde yayınlanmış vaka serilerinde kardiyovasküler tutulumunMPS’ye sıklıkla eşlik ettiği belirtilmektedir. MPS’li hastalarda en sık görülen kardiyakbulgular, mitral kapakta kalınlaşma ve buna eşlik edebilen prolapsus, yetersizlik vedaha az sıklıkla darlıklardır. Bu çalışma ile MPS tanısı alan hastalarda mukopolisakkaridozlar ve kalp tutulumununirdelenmesi amaçlanmıştır.Gereç ve Yöntem: Bu çalışmada 2005-2009 yılları arasında mukopolisakkaridoz tanısınedeniyle kardiyak inceleme amacıyla bölümümüze gönderilen 11 hastanın 5 erkek,6 kız kardiyak bulguları geriye dönük olarak değerlendirildi. Kardiyak değerlendirmefizik muayene, elektrokardiyografi, telekardiyografi ve ekokardiyografik inceleme ilegerçekleştirildi.Bulgular: Hastaların başvuru yaşı 1,5 ile 14 yıl arasında değişiyordu ve yaş ortalaması7,44±5,35 ortanca 7 yıl idi. MPS tip II ve tip IV üçer hastada saptanmıştı. Tip I iki hastadatip VI ise bir hastada mevcuttu. İki hastanın tiplendirilmesi henüz sonuçlanmamıştı.Hastaların tamamında mitral kapak, 4’ünde %36,3 mitral kapak tutulumuna ilaveten aortkapak tutulumu ve ikisinde ise ilaveten triküspit kapak tutulumu vardı. Bir hastada interventriküler septumda ve sol ventrikül arka duvarda hipertrofi mevcuttu. Pulmonerhipertansiyon ise sadece 1 hastada saptandı. Hastaların hiçbirinde herhangi bir ritm problemi bulunmadı.Sonuç: Mukopolisakkaridozlarda kardiyak tutulum sıktır. Mitral kapak anormalliklerien sık görülen bulgudur. MPS tanısıyla takip edilen hastaların ekokardiyografikincelemeleri, asemptomatik olsalar dahi rutin olarak yapılmalı ve aralıklarla tekrarlanmalıdır

🔖

Cite This Article

Babaoğlu, K., Özsoy, G., Binnetoğlu, K. (2010). Cardiac Involvement in Mucopolysaccharidoses. Güncel Pediatri, Cilt: 8 Sayı: 3, 48–51. https://ajindex.com/articles/1401125

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Krovetz LJ, Lorincz AE, Schiebler GL. Cardiovascular manifestations of the Hurler syndrome. Hemodinamic and angiocardiographic observations in 15 patients. Circulation 1965;31:132-41.
  2. Nelson J, Shields MD, Mulholland HC. Cardiovascular studies in the mucopolysaccharidoses. J Med Genet 1990;27:94-100.
  3. Gross DM, Williams JC, Caprioli C, Dominguez B, Howell RR. Cardiovascular changes in MPS Echocardiographic abnormalities in the mucopolysaccharide storage diseases. Am J Cardiol 1988;61:170-6.
  4. Renteria VG, Ferrans VJ, Roberts WC. The heart in the Hurler syndrome. Gross, histological and ultrastructural observations in five necropsy cases. Am J Cardiol 1976;38:487-501.
  5. Dangel JH. Cardiovascular changes in children with mucopolysaccharide storage diseases and related disorders--clinical and echocardiographic findings in 64 patients. Eur J Pediatr 1998;157:534-8.
  6. Rigante D, Segni G. Cardiac structural involvement in mucopolysaccharidoses. Cardiology 2002;98:18-20.
  7. Johnson GL, Vine DL, Cottrill CM, Noonan JA. Echocardiographic mitral valve deformity in the mucopolysaccharidoses. Pediatrics 1981;67:401-6.
  8. Mohan UR, Hay AA, Cleary MA, Wraith JE, Patel RG. Cardiovascular changes in children with mucopolysaccharide disorders. Acta Pediatr 2002;91:799-804.
  9. Wippermann CF, Beck M, Schranz D, Huth R, MichelBehnke I, Jüngst BK. Mitral and aortic regurgitation in 84 patients with mucopolysaccaridoses. Eur J Pediatr 1995;154:98-101.
  10. Braunlin EA, Berry JM, Whitley CB. Cardiac findings after enzyme replacement therapy for mucopolysaccharidosis type I. Am J Cardiol 2006;98:416-8.
  11. Temizhan M, Ezgü FS, Tümer L, Gündüz M, Hasano¤lu A. Mukopolisakkaridoz Tip 1’li hastada Laronidase tedavisi: 7 ayl›k sonuçlar. Türkiye Klinikleri J Pediatr Sci 2005;1:9-11.
  12. Fesslová V, Corti P, Sersale G, Rovelli A, Russo P, Mannarino S et al. The natural course and the impact of therapies of cardiac involvement in the mucopolysaccharidoses. Cardiol Young 2009;19:170-8.